TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33993893

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 4950

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 4950

Group type: EXPERIMENTAL
Intervention: RBC transfusions of >3 units
Number of subjects: 4950

Group type: EXPERIMENTAL
Intervention: RBC transfusions of 0-3 units
Number of subjects: 4950
Study: 35623048

Group type: EXPERIMENTAL
Intervention: 10-day antibiotic therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: 20-day antibiotic therapy
Number of subjects: 66
Study: 34098395

Group type: EXPERIMENTAL
Intervention: Fibrinogen (2 g fibrinogen concentrate diluted in 100 ml distilled water, intravenously 15-30 min before surgery)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (100 ml normal saline, intravenously 15-30 min before surgery)
Number of subjects: 70
Study: 32277749

Group type: EXPERIMENTAL
Intervention: Gospel music program with weekly, 45-minute vocal and instrumental sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gospel music program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiovascular lifestyle education sessions alone (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 35488866

Group type: EXPERIMENTAL
Intervention: REACH+ intervention consisting of behavior, cognitive, and motivation components, food monitoring, and a skill consolidation phase delivered via outpatient telehealth sessions for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 35654820

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) and 6-mercaptopurine (6-MP) as maintenance therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiopurine Enhanced ALL Maintenance (TEAM) strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucocorticosteroid/vincristine pulses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0
Study: 34001277

Group type: EXPERIMENTAL
Intervention: Mindful Living with Challenge (MLWC) intervention
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 1600
Study: 32965249

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg per day with titration of 100 mg once a month + synbiotic 1 capsule three times a day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Allopurinol monotherapy
Number of subjects: 68
Study: 34264316

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (3 mg/kg every 2 weeks + 1 mg/kg every 6 weeks)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Nivolumab alone (3 mg/kg every 2 weeks)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 252

Group type: COMPARATOR
Intervention: Nivolumab alone
Number of subjects: 252
Study: 33217031

Group type: EXPERIMENTAL
Intervention: Lidocaine group (group L, n = 40) received 1‐mg midazolam, 1.5 mg/kg lidocaine, and 1 mg/kg propofol intravenously
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (group C, n = 40) received 1‐mg midazolam, saline in the same volume as the lidocaine group, and 1 mg/kg propofol intravenously
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine group (group L)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 80
Study: 32628922

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant (0.59 mg)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Systemic therapy (corticosteroid plus immunosuppression)
Number of subjects: 232
Study: 33913373

Group type: EXPERIMENTAL
Intervention: Thiamin 90 mg/day combined with folic acid 30 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonintervention (Control)
Number of subjects: 50
Study: 32555047

Group type: EXPERIMENTAL
Intervention: Ibuprofen (NSAID)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (Acetaminophen)
Number of subjects: 102
Study: 35673085

Group type: EXPERIMENTAL
Intervention: Intervention snippets from 261 randomized clinical trial (RCT) abstracts
Number of subjects: 0
Study: 34486352

Group type: EXPERIMENTAL
Intervention: 75 kg ha⁻¹ phosphorus and 8.0 t ha⁻¹ lime
Number of subjects: 16
Study: 36228734

Group type: EXPERIMENTAL
Intervention: Vonoprazan, 20 mg
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Vonoprazan, 10 mg
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Lansoprazole, 30 mg
Number of subjects: 1024
Study: 33905836

Group type: EXPERIMENTAL
Intervention: Strabismus surgery
Number of subjects: 197
Study: 32227638

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (alteplase)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: DWI-FLAIR mismatch
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: PWI-DWI mismatch
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Mismatch screening
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: PWI-DWI mismatch status
Number of subjects: 431
Study: 35760566

Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) intervention; patients received an oncologist letter supporting them to request a GP review along with a patient information leaflet about ACP.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Quality of life measures (EuroQol EQ-5D-5L and ICECAP Supportive Care Measure) at baseline, 6, 12, 24, and 48 weeks.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring patient, carer, and GP experiences.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Psychological or clinical harms assessment.
Number of subjects: 46
Study: 33667726

Group type: EXPERIMENTAL
Intervention: KHK inhibitor PF‐06835919
Number of subjects: 2

Group type: COMPARATOR
Intervention: Single oral doses of PF‐06835919
Number of subjects: 2
Study: 35803627

Group type: EXPERIMENTAL
Intervention: Online self-management fall prevention intervention (group-based, six 2-hour weekly sessions, plus a booster session 8 weeks later)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (received a brochure about fall risk factors and fall prevention)
Number of subjects: 48
Study: 33373553

Group type: EXPERIMENTAL
Intervention: Telehealth sessions
Number of subjects: 200
Study: 36429821

Group type: EXPERIMENTAL
Intervention: Network psychometrics methodology
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Network centrality measures (eigencentrality, strength, bridge centrality)
Number of subjects: 367
Study: 33565359

Group type: EXPERIMENTAL
Intervention: Uroflowmetry (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Urodynamic study (Group B)
Number of subjects: 50
Study: 36056176

Group type: EXPERIMENTAL
Intervention: Loss-framing of information on vaccine effectiveness
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: BioNTech brand, higher efficacy, less serious adverse events, more vaccination coverage in children
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Presentation of mortality information
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Parental uptake of the COVID-19 vaccine
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Children's age
Number of subjects: 298
Study: 34793646

Group type: EXPERIMENTAL
Intervention: RFT through foramen rotundum (RFT-FR)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RFT through foramen ovale (RFT-FO)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RFT-FR
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RFT-FO
Number of subjects: 70
Study: 36216768

Group type: EXPERIMENTAL
Intervention: Urinary cotinine (UCot) measurements categorized into three groups
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Hypofractionated breast RT
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Smoking (as indicated by UCot)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Light smoker/secondhand smoke exposure (as indicated by UCot)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Not applicable (acute RISI)
Number of subjects: 980
Study: 34143241

Group type: EXPERIMENTAL
Intervention: Consecutive practice (INT consecutive)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Concurrent practice (INT concurrent)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 45
Study: 32040044

Group type: EXPERIMENTAL
Intervention: Monoclonal anti‐Aβ antibodies (bapineuzumab, solanezumab, gantenerumab, crenezumab, aducanumab)
Number of subjects: 0
Study: 35196381

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) telephone-delivered coaching
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Standard quitline (QL) telephone-delivered coaching
Number of subjects: 1170
Study: 34325886

Group type: EXPERIMENTAL
Intervention: MitraClip plus guideline-directed medical therapy (GDMT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 614
Study: 32336045

Group type: EXPERIMENTAL
Intervention: GDNF-DNMG-modified DNM-S (DNM-S/GDNF@DNMG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DNM-S
Number of subjects: 15

Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 15
Study: 35181219

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 33640581

Group type: EXPERIMENTAL
Intervention: Genetically determined copper levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically determined zinc levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically determined calcium levels
Number of subjects: 0
Study: 35513775

Group type: EXPERIMENTAL
Intervention: Partners with secondary or higher education
Number of subjects: 519

Group type: COMPARATOR
Intervention: Partners with less than secondary education
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Partners’ education level
Number of subjects: 519
Study: 33399411

Group type: EXPERIMENTAL
Intervention: Anal inserts
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 32536587

Group type: EXPERIMENTAL
Intervention: Dual-cured self-adhesive cement without pretreatment (Group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-cured self-adhesive cement after polyacrylic acid treatment (Group II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-cured self-adhesive cement with universal dentin adhesive pre-cure method (Group III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-cured self-adhesive cement with universal dentin adhesive co-cure method (Group IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-cure mode cementation (Group V)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Panavia V5 (Kuraray Noritake) - Control group
Number of subjects: 0
Study: 36016763

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine (CAF)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of 150 mg caffeine, 100 mg methylliberine, and 50 mg theacrine (CMT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 48
Study: 32692990

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) infiltration of the BMG harvest site
Number of subjects: 43

Group type: COMPARATOR
Intervention: No further local anesthetic infiltration (Control)
Number of subjects: 43
Study: 35550457

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA), 24 sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture, 24 sessions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study: 32516839

Group type: COMPARATOR
Intervention: COVID-19 convalescent plasma (CCP) therapy, 200-400 ml of plasma collected from donors with antibody titres > 1:160.
Number of subjects: 700
Study: 35037816

Group type: EXPERIMENTAL
Intervention: Lenzilumab plus standard of care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenzilumab plus SOC
Number of subjects: 0
Study: 34006540

Group type: EXPERIMENTAL
Intervention: Integrated community-based (ICB) care
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 900
Study: 32959583

Group type: EXPERIMENTAL
Intervention: Dynamic scalp acupuncture combined with task-oriented mirror therapy (TOMT)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with TOMT
Number of subjects: 78

Group type: COMPARATOR
Intervention: Task-oriented mirror therapy (TOMT)
Number of subjects: 78
Study: 35209951

Group type: EXPERIMENTAL
Intervention: Blood pressure targets of 63 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure targets of 77 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restrictive oxygen concentration (9–10 kPa) during mechanical ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liberal oxygen concentration (13–14 kPa) during mechanical ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Device-based active fever management discontinued after 36 h or 72 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care including targeted temperature management at 36 °C for 24 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to initiation of renal replacement therapy or death
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) level at 48 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOCA score at day 90
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Ranking Scale (mRS) and CPC at 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NT-pro-BNP at 90 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eGFR and LVEF at 90 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily cumulated vasopressor requirement during ICU stay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Need for a combination of vasopressors and inotropic agents or mechanical circulatory support
Number of subjects: 0
Study: 33496396

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) pathway
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard pathway
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: POC pathway
Number of subjects: 124
Study: 36273185

Group type: EXPERIMENTAL
Intervention: Screening and intervention (includes parent-report child anxiety screening questionnaire, feedback on screening outcomes, lesson on managing fears and worries, and OSI offered to parents of children who screen positive)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Usual school practice (assessment and usual school practice only)
Number of subjects: 398
Study: 33844258

Group type: EXPERIMENTAL
Intervention: Pneumatic uterine bracket set at 260 mmHg (Group B)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Pneumatic uterine bracket set at 280 mmHg (Group C)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group with pneumatic uterine bracket set at 240 mmHg (Group A)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Pneumatic uterine bracket set at 240 mmHg (Group A)
Number of subjects: 148
Study: 33522636

Group type: EXPERIMENTAL
Intervention: Preceptors' education intervention (face-to-face education about orientation)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study: 32139505

Group type: EXPERIMENTAL
Intervention: Golodirsen (30 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 35744082

Group type: EXPERIMENTAL
Intervention: Decellularized bovine peritoneum (DBP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 33639181

Group type: EXPERIMENTAL
Intervention: HPV vaccination (three doses of Cervarix®)
Number of subjects: 6226

Group type: COMPARATOR
Intervention: Non-HPV vaccination (reference cohort)
Number of subjects: 6226
Study: 32651047

Group type: EXPERIMENTAL
Intervention: Section 8 rental voucher (treatment group)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Peer drug use (mediator)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Public housing (control group)
Number of subjects: 750
Study: 36278480

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT) combined with attentional bias modification training (ABM)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy (ICBT) combined with ABM placebo
Number of subjects: 63
Study: 32909439

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) injections
Number of subjects: 187
Study: 35797024

Group type: EXPERIMENTAL
Intervention: Saline nasal irrigation (SNI) with 400 mg theophylline
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline nasal irrigation (SNI) with placebo (500 mg lactose powder)
Number of subjects: 51
Study: 33825587

Group type: EXPERIMENTAL
Intervention: Baduanjin Qigong (8 weeks, 3 sessions per week followed by home-based practice 3 days a week for another 8 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional fitness training (2 sessions in the first week followed by home-based exercise practice 3 days a week until week 16)
Number of subjects: 58
Study: 97175823

Group type: EXPERIMENTAL
Intervention: Preoperative ERC with ESE followed by LC during the same hospital admission (Group A)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Single stage laparoscopic management consisting of LC and laparoscopic stone extraction (Group B)
Number of subjects: 207
Study: 35243022

Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR) in combination with ongoing systemic therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard of care (switch to the next line of treatment, continue same treatment or observation)
Number of subjects: 68
Study: 33409726

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 183
Study: 36421329

Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarette plus support
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Nicotine-free e‐cigarette plus support
Number of subjects: 210

Group type: COMPARATOR
Intervention: Support
Number of subjects: 210
Study: 34159208

Group type: EXPERIMENTAL
Intervention: Overall PRP group (intraoperative PRP augmentation)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no PRP treatment)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall PRP group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: PRP-booster group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: PRP-only group
Number of subjects: 58
Study: 36201709

Group type: EXPERIMENTAL
Intervention: Improving shared decision making (SDM)
Number of subjects: 173
Study: 33612080

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 186
Study: 32729615

Group type: EXPERIMENTAL
Intervention: early time-restricted feeding (eTRF)
Number of subjects: 16
Study: 35060543

Group type: EXPERIMENTAL
Intervention: Lung-conduction exercises (LCE), medication + LCE, 5 times a week, n = 8
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR), medication + PR, 5 times a week, n = 8
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard care (SC), only medication, n = 9
Number of subjects: 25
Study: 33846054

Group type: EXPERIMENTAL
Intervention: C-R/R using autodialer in Colorado
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: C-R/R using mail in Colorado
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: C-R/R using autodialer in New York
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: C-R/R using text in New York
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group in Colorado
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group in New York
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: C-R/R overall
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Cost per adolescent for mail
Number of subjects: 224
Study: 34473334

Group type: EXPERIMENTAL
Intervention: Curcuminoids (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 32534252

Group type: EXPERIMENTAL
Intervention: Active rTMS (10Hz, 3000 pulses each session)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 42
Study: 34970882

Group type: EXPERIMENTAL
Intervention: Acupoint injection of vitamin B1 into ST36 and LI4, once every other day, three times a week.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mosapride citrate tablets (5 mg) taken orally 30 min before each of the three meals.
Number of subjects: 100
Study: 35811251

Group type: EXPERIMENTAL
Intervention: Oral Acetazolamide 20 mg/kg/day in 3-4 divided doses for 7 days plus Corrected body (prone) position (CP+A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Corrected body (prone) position alone (CP-A)
Number of subjects: 72
Study: 33515093

Group type: EXPERIMENTAL
Intervention: Oily fish (300 g/week)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Poultry
Number of subjects: 199
Study: 615007039

Group type: EXPERIMENTAL
Intervention: rhSA treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36458140

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri DSM 17938 probiotic recipients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 33378520

Group type: EXPERIMENTAL
Intervention: Bromelain enzyme pre-rinse
Number of subjects: 43

Group type: COMPARATOR
Intervention: Powdered-sugar placebo pre-rinse
Number of subjects: 43
Study: 32783220

Group type: EXPERIMENTAL
Intervention: Microcurrent electrotherapy (EE)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sham application (control)
Number of subjects: 53
Study: 32706948

Group type: EXPERIMENTAL
Intervention: Trigger Tool (TT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Voluntary notification platform (SNEA)
Number of subjects: 201